Pentosan polysulfate inhibits atherosclerosis in Watanabe heritable hyperlipidemic rabbits: Differential modulation of metalloproteinase-2 and -9

Laboratory Investigation

Volumn 92, Issue 2, 2012, Pages 236-245

  Lupia, Enrico ^a,b   Zheng, Feng ^c   Grosjean, Fabrizio ^a,d   Tack, Ivan ^e   Doublier, Sophie ^b   Elliot, Sharon J ^f   Vlassara, Helen ^a   Striker, Gary E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c FUJIAN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF PAVIA   (Italy)

^e CHU RANGUEIL   (France)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; heparin like; lipids; macrophages; metalloproteinases; TNF

Indexed keywords

COLLAGEN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; LIVER TRIACYLGLYCEROL LIPASE; PENTOSAN POLYSULFATE; SYNAPTOPHYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA INTIMA; AORTA MEDIA; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ATHEROSCLEROSIS; CELL LINE; ENZYME ACTIVATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNOHISTOCHEMISTRY; LIPIDS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PENTOSAN SULFURIC POLYESTER; RABBITS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856456741     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.154     Document Type: Article

References (46)

1. Engelberg H. Actions of heparin in the atherosclerotic process. Pharmacol Rev 1996;48:327-352. (Pubitemid 26196590)
2. Rogers C, Welt FG, Karnovsky MJ, et al. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996;16:1312-1318. (Pubitemid 26339721)
3. Kenagy RD, Nikkari ST, Welgus HG, et al. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Invest 1994;93:1987-1993. (Pubitemid 24143077)
4. Shibata Y, Abiko Y, Goto K, et al. Heparin stimulates the collagen synthesis in mineralized cultures of the osteoblast-like cell line, MC3T3-E1. Biochem Int 1992;28:335-344.
5. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996;7:330-335. (Pubitemid 26372454)
6. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775-778. (Pubitemid 24242744)
7. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90: 251-262. (Pubitemid 34633925)
8. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006;69:625-635. (Pubitemid 43139725)
9. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007;17:253-258. (Pubitemid 350087694)
10. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75:346-359. (Pubitemid 350298459)
11. Newby AC, George SJ, Ismail Y, et al. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost 2009;101:1006-1011.
12. Davis EL, El Khoudary SR, Talbott EO, et al. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol 2008;179:177-185. (Pubitemid 350216757)
13. Bobadilla NA, Tack I, Tapia E, et al. Pentosan polysulfate prevents glomerular hypertension and structural injury despite persisting hypertension in 5/6 nephrectomy rats. J Am Soc Nephrol 2001;12:2080-2087. (Pubitemid 32880344)
14. Elliot SJ, Striker LJ, Stetler-Stevenson WG, et al. Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells. J Am Soc Nephrol 1999;10:62-68. (Pubitemid 29034943)
15. Elliot SJ, Striker LJ, Connor E, et al. Pentosan polysulfate decreases proliferation and extracellular matrix deposition by vascular smooth muscle cells isolated from failed hemodialysis access grafts. Clin Nephrol 2000;54:121-127. (Pubitemid 30625629)
16. Elliot SJ, Zorn BH, McLeod DG, et al. Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover. Prostate Cancer Prostatic Dis 2003;6:138-142. (Pubitemid 36798381)
17. Shiomi M, Ito T, Tsukada T, et al. Cell compositions of coronary and aortic atherosclerotic lesions in WHHL rabbits differ. An immunohistochemical study. Arterioscler Thromb 1994;14:931-937.
18. Iverius PH, Brunzell JD. Human adipose tissue lipoprotein lipase: changes with feeding and relation to postheparin plasma enzyme. Am J Physiol 1985;249:E107-E114. (Pubitemid 15031738)
19. Shindo J, Ishibashi T, Yokoyama K, et al. Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits. Circulation 1999;99:2150-2156. (Pubitemid 29196800)
20. Valone FH, Epstein LB. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. J Immunol 1988;141:3945-3950.
21. Camussi G, Bussolino F, Salvidio G, et al. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 1987;166:1390-1404. (Pubitemid 18051430)
22. Jacot TA, Striker GE, Stetler-Stevenson M, et al. Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. Lab Invest 1996;75:791-799. (Pubitemid 26427665)
23. Welgus HG, Campbell EJ, Cury JD, et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest 1990;86:1496-1502. (Pubitemid 20372596)
24. Herrera-Acosta J, Tapia E, Sánchez-Lozada LG, et al. Restoration of glomerular haemodynamics and renal injury independent of arterial hypertension in rats with subtotal renal ablation. J Hypertens Suppl 2002;20:S29-S35.
25. Guan Z, Fuller BS, Yamamoto T, et al. Pentosan polysulfate treatment preserves renal autoregulation in Ang II-infused hypertensive rats via normalization of P2X1 receptor activation. Am J Physiol Renal Physiol 2010;298:1276-1284.
26. Nickel JC, Forrest J, Barkin J, et al. Safety and efficacy of up to 900 mg/day polysulfate sodium (elmiron) in patients with interstitial cystitis. Urology 2001;57:122-123.
27. Striker GE, Lupia E, Elliot S, et al. Glomerulosclerosis, arteriosclerosis, and vascular graft stenosis: treatment with oral heparinoids. Kidney Int Suppl 1997;63:S120-S123. (Pubitemid 28020449)
28. Schwedler SB, Bobadilla N, Striker LJ, et al. Pentosan polysulfate treatment reduces cyclosporine-induced nephropathy in salt-depleted rats. Transplantation 1999;68:1583-1588.
29. Smith MM, Ghosh P, Numata Y, et al. The effects of orally administered calcium pentosan polysulfate on inflammation and cartilage degradation produced in rabbit joints by intraarticular injection of a hyaluronate-polylysine complex. Arthritis Rheum 1994;37:125-136. (Pubitemid 24027703)
30. Tanhehco EJ, Kilgore KS, Naylor KB, et al. Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate. J Cardiovasc Pharmacol 1999;34:153-161. (Pubitemid 29296151)
31. Kilgore KS, Naylor KB, Tanhehco EJ, et al. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther 1998;285:987-994. (Pubitemid 28277895)
32. Tanaka Y, Adams DH, Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today 1993;14:111-115. (Pubitemid 23068293)
33. Sadhukhan PC, Tchetgen MB, Rackley RR, et al. Sodium pentosan polysulfate reduces urothelial responses to inflammatory stimuli via an indirect mechanism. J Urol 2002;168:289-292. (Pubitemid 34640846)
34. Sukhova GK, Schönbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-2509. (Pubitemid 29228279)
35. Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006;37:235-239. (Pubitemid 43732079)
36. de Nooijer R, Verkleij CJ, von der Thüsen JH, et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 2006;26:340-346. (Pubitemid 43732197)
37. Gough PJ, Gomez IG, Wille PT, et al. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 2006;116:59-69. (Pubitemid 43121791)
38. Kuzuya M, Nakamura K, Sasaki T, et al. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2006;26:1120-1125. (Pubitemid 43732121)
39. Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004;109:1408-1414. (Pubitemid 38387828)
40. Johnson JL, Baker AH, Oka K, et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 2006;113:2435-2444. (Pubitemid 43948051)
41. Rouis M, Adamy C, Duverger N, et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E deficient mice. Circulation 1999;100:533-540. (Pubitemid 29360163)
42. Lemaitre V, Soloway PD, D'Armiento J. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 2003;107:333-338. (Pubitemid 36135233)
43. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res 2002;90: 897-903. (Pubitemid 34633882)
44. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007;211:19-26. (Pubitemid 46363892)
45. Deli MA, Abraham CS, Takahata H, et al. Pentosan polysulfate regulates scavenger receptor-mediated, but not fluid-phase, endocytosis in immortalized cerebral endothelial cells. Cell Mol Neurobiol 2000;20:731-745.
46. Zugmaier G, Favoni R, Jaeger R, et al. Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors. Ann NY Acad Sci 1999;886:243-248. (Pubitemid 30042449)